The identification of potent and selective imidazole-based inhibitors of B-Raf kinase

Pearson, 2001, Endocr. Rev., 22, 153, 10.1210/er.22.2.153 Davies, 2002, Nature, 417, 949, 10.1038/nature00766 Chang, 2003, Int. J. Oncol., 22, 469 Hilger, 2002, Onkologie, 25, 511, 10.1159/000068621 Irving, 2000, Mol. Brain Res., 77, 65, 10.1016/S0169-328X(00)00043-7 Namura, 2001, Proc. Natl. Acad. Sci. U.S.A, 98, 11569, 10.1073/pnas.181213498 Wang, 2003, J. Pharmacol. Exp. Ther., 304, 172, 10.1124/jpet.102.040246 Heimbrook, D. C.; Huber, H. E.; Stirdivant, S. M.; Patrick, D. R.; Claremon, D.; Liverton, N.; Selnick, H.; Ahern, J.; Conroy, R.; Drakas, R.; Falconi, N.; Hancock, P.; Robinson, R.; Smith, G.; Olif, A. American Association for Cancer Research, New Orleans, April 1998 poster #3793. Compound activity is determined as either the ability of test compounds to inhibit B-Raf mediated phosphorylation of kinase dead MEK (data expressed as IC50) or as a B-Raf-binding affinity derived from the fluorescent ligand displacement assay (FP, data expressed as Kd). For assay details, see Dean, D. K.; Takle, A. K.; Wilson, D. M. PCT Int. Appl. WO 02/24680. Adams, 2001, Prog. Med. Chem., 38, 1, 10.1016/S0079-6468(08)70091-2 Davies, 2000, Biochem. J., 351, 95, 10.1042/0264-6021:3510095 Gallagher, 1997, Bioorg. Med. Chem., 5, 49, 10.1016/S0968-0896(96)00212-X